Study on the metabolic process of synthetic cannabinoids 4F-MDMB-BINACA and 4F-MDMB-BICA in human liver microsome and zebrafish model via UHPLC-QE Orbitrap MS

Li, Huan; Qian, Zhenhua; Zhao, Yanbiao; Zheng, Hui

doi:10.1007/s00216-022-04034-2

Cited by 5 publications

(1 citation statement)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At present, the combination of ultra-high-performance liquid chromatography-high-resolution mass spectrometry (UHPLC-HRMS) has been widely used for the in-depth analysis of drug metabolites [ 18 ]. UHPLC-HRMS shows its superiority of high sensitivity, high selectivity, and high mass accuracy in structural identification [ 19 , 20 ]. Recently, UHPLC-Q-Exactive Plus Orbitrap MS has been used for improving the efficiency of metabolite identification.…”

Section: Introductionmentioning

confidence: 99%

Metabolites Identification and Mechanism Prediction of Neobavaisoflavone In Vitro and In Vivo of Rats through UHPLC-Q-Exactive Plus Orbitrap MS Integrated Network Pharmacology

Fan

Wang

et al. 2022

Molecules

View full text Add to dashboard Cite

Neobavaisoflavone is an important isoflavone component isolated from Psoraleae Fructus. It is used extensively worldwide because of its antibacterial, antioxidant, anti-inflammatory, anticancer, and anti-osteoporotic activities. However, there is no systematic and comprehensive research on the metabolism of neobavaisoflavone in vivo and in vitro. The study aimed to analyze the metabolic characteristics and mechanism of neobavaisoflavone for the first time. Firstly, biological samples were pretreated by the solid-phase extraction (SPE) method, methanol precipitation, and acetonitrile precipitation. Secondly, the samples were analyzed on UHPLC-Q-Exactive Plus Orbitrap MS. Thirdly, metabolites were tentatively identified based on retention time, parallel reaction monitoring strategy, diagnostic product ions, and neutral loss fragments. A total of 72 metabolites of neobavaisoflavone were tentatively identified, including 28 in plasma, 43 in urine, 18 in feces, six in the liver, and four in the liver microsome. The results suggested that neobavaisoflavone mainly underwent glucuronidation, sulfation, hydroxylation, methylation, cyclization, hydration, and their composite reactions in vivo and in vitro. In addition, nine active components with high bioavailability and 191 corresponding targets were predicted by the Swiss Drug Design database. The 1806 items of GO and 183 KEGG signaling pathways were enriched. These results showed that metabolites expanded the potential effects of neobavaisoflavone. The present study would provide the scientific basis for the further exploitation and application of neobavaisoflavone.

show abstract

Section: Introductionmentioning

confidence: 99%

Metabolites Identification and Mechanism Prediction of Neobavaisoflavone In Vitro and In Vivo of Rats through UHPLC-Q-Exactive Plus Orbitrap MS Integrated Network Pharmacology

Fan

Wang

et al. 2022

Molecules

View full text Add to dashboard Cite

show abstract

An ultra-high-performance liquid chromatography-quadrupole-orbitrap mass spectrometry based metabolomics investigation on pacific oysters (Crassostrea gigas) during depuration and anhydrous living-preservation

Bi,

Gong,

Zhu

et al. 2024

Food Bioscience

View full text Add to dashboard Cite

Insights into the metabolism of CH-PIATA—A novel synthetic cannabinoid featuring an acetamide linker

Zschiesche,

Scheu,

Thieme

et al. 2024

Journal of Analytical Toxicology

View full text Add to dashboard Cite

The recent change from the popular carboxamide to an acetamide (ATA) linker scaffold in synthetic cannabinoid receptor agonists (SCRAs) can be interpreted as an attempt to circumvent legal regulations, setting new analytical challenges. Metabolites of N-cyclohexyl-2-(1-pentyl-1H-indol-3-yl)acetamide: CH-PIATA, the second ATA type SCRA detected in the EU, were investigated in urine and serum samples by LC–HRMS-MS and LC–MS-MS. Two different in vitro models: a pHLM assay and HepG2-cells as well as an in silico prediction by GLORYx freeware assisted in metabolite formation/identification. CH-PIATA was extensively metabolized, leading to metabolites formed primarily by mono- and dihydroxylation. For urine and serum specimens, monohydroxylation at the indole core or the methylene spacer of the acetamide linker (M1.8), carboxylic acid formation at the N-pentyl side chain (M3.1), and degradation of the latter leading to a tentatively identified N-propionic acid metabolite (M5.1) are suggested as reliable markers for substance intake. The N-propionic acid metabolite could not be confirmed in the in vitro assays as it includes multiple consecutive metabolic reactions. Furthermore, CH-PIATA could be detected as parent substance in blood samples, but not in urine. Both in vitro assays and the in silico tool proved suitable for predicting metabolites of CH-PIATA. Considering effort and costs, pHLM incubations seem to be more effective for metabolite prediction in forensic toxicology. The highlighted phase I metabolites serve as reliable urinary targets for confirming CH-PIATA use. The in silico approach is advantageous when reference material is unavailable.

show abstract

Study on the metabolic process of synthetic cannabinoids 4F-MDMB-BINACA and 4F-MDMB-BICA in human liver microsome and zebrafish model via UHPLC-QE Orbitrap MS

Cited by 5 publications

References 18 publications

Metabolites Identification and Mechanism Prediction of Neobavaisoflavone In Vitro and In Vivo of Rats through UHPLC-Q-Exactive Plus Orbitrap MS Integrated Network Pharmacology

Metabolites Identification and Mechanism Prediction of Neobavaisoflavone In Vitro and In Vivo of Rats through UHPLC-Q-Exactive Plus Orbitrap MS Integrated Network Pharmacology

An ultra-high-performance liquid chromatography-quadrupole-orbitrap mass spectrometry based metabolomics investigation on pacific oysters (Crassostrea gigas) during depuration and anhydrous living-preservation

Insights into the metabolism of CH-PIATA—A novel synthetic cannabinoid featuring an acetamide linker

Contact Info

Product

Resources

About